Biomedical subjects

Marek Jarema

Publications and source records attributed to Marek Jarema.

6 recordsLinked to original sources

PubMedDate not supplied

[The change of quality of life and clinical picture in schizophrenia].

The aim of the study was to determine how the quality of life changes during antipsychotic treatment in schizophrenia and whether there is any correlation between the change of quality of life and the change of clinical picture in 232 patients with the diagnosis of schizophrenia treated for 8 weeks with antipsychotic medication. The mental status improved significantly during treatment while patients' quality of life improved insignificantly. Severity of schizophrenic symptoms correlated negatively with patients' quality of life before treatment but not after treatment. Clinical improvement of schizophrenic symptomatology correlated negatively with the improvement of patients' quality of life. After treatment the quality of life was significantly worse in patients who had distinct depression before treatment, than in those without depression or with only slight depression before treatment.

Adult↗

PubMedDate not supplied

[Second generation of neuroleptics--expectations and the reality].

The expectations regarding the successful treatment of psychotic disorders, especially schizophrenia, are quite high. By introduction of the antipsychotic drugs of second generation, the hope of better efficacy and tolerability has arisen. Up to now, basing on the clinical experience it seems that the efficacy of II generation antipsychotics reflects not only the positive but also the negative as well as affective schizophrenic symptoms. These drugs do not worsen the cognitive functioning of patients, but sometimes even improve some cognitive functions. Their tolerability is in general better in comparison to the classic neuroleptics, but sometimes it happens that unfavorable drug-induced side-effects during treatment (e.g. extrapyramidal symptoms) may occur. The careful selection of the drug and its dosage increases the possibility of good clinical improvement, but more wider use of these drugs is recommended in order to evaluate their practical usefulness.

Antipsychotic Agents↗

PubMedDate not supplied

[Second generation antipsychotics: similarities and differences].

Second generation antipsychotics share some similarities but display also differences in their action. The pharmacological profile as well as the clinical efficacy and tolerability of these drugs currently on the market in Poland have been described. The analysis of their properties reveals distinct differences between the drugs. Those differences underline the value of the medications in the treatment of psychotic disorders. The differences allow tailoring the antipsychotic therapy to the individual needs of each single patient. Such a possibility to use the pharmacological agents according to the needs of the patient makes an important feature of the second generation drugs. At the same time it indicates that obvious differences in action exist inside the group.

Antipsychotic Agents↗

PubMedDate not supplied

[Current concepts of pharmacological treatment in schizophrenia].

The modern concepts of pharmacotherapy of schizophrenia, with the special emphasis put on new antipsychotic drugs were presented. The attention was put on the need for careful evaluation of the patient's state: the diagnosis, treatment which the patient receives and compliance with the treatment. It was stated that modern concepts of treatment of schizophrenia do not solely rely on the use of modern drugs, but include the multidirectional therapeutic actions with an active participation of the patient and his/her relatives.

Antipsychotic Agents↗

PubMedDate not supplied

[Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial].

AIM: The primary objective of the study was to evaluate the severity of extrapyramidal symptoms during treatment with olanzapine (10-20 mg) versus perphenazine (8-40 mg) using the Simpson Angus Scale (SAS). The secondary objective was to assess the safety profile and clinical efficacy of the investigated drugs. MATERIAL AND METHOD: A total of 95 patients with schizophrenia who met the criteria for DSM-IV were randomized to a double-blind, 18 week prospective comparative trail conducted in Poland. The tolerance of treatment was assessed with the use of scales: BAS, SAS and UKU. The efficacy of treatment was evaluated with BPRS, PANSS and CGOI scales. RESULTS: For olanzapine patients, the severity of extrapyramidal symptoms improved after 3 first weeks of treatment, and significantly decreased from the baseline to endpoint. Perphenazine patients showed an increase of extrapyramidal symptoms. The difference of the SAS scores change was statistically significant between olanzapine and perphenazine groups. Akathisia symptoms decreased significantly in the olanzapine group during the treatment period, whereas symptoms of akathisia increased in the perphenazine group. Statistically significant differences of mean change of BAS total score from baseline to endpoint were noted between treatment groups Treatment--emergent adverse events occurred more frequently in patients receiving perphenazine (46%), than in patients receiving olanzapine (17%). The proportion of patients complying with improvement criteria for CGI scale score was statistically greater in the olanzapine group (72.7%) than in the perphenazine group (47.9%). Results of this study showed that the tolerance profile in patients taking olanzapine is superior to perphenazine. CONCLUSIONS: Olanzapine was better tolerated than perphenazine. After olanzapine treatment more subjects fulfilled the criterion of improvement and schizophrenic symptoms were less severe than in patients treated with perphenazine.

Antipsychotic Agents↗

PubMedDate not supplied

[Subjective and objective evaluation of olanzapine treatment in schizophrenia].

AIM: The study was to evaluate objectively (by a physician) and subjectively (by the patients) the efficacy of 12-months olanzapine treatment of schizophrenic out-patients. METHOD: Olanzapine treatment was either initiated or patients were switched from other antipsychotics to olanzapine. Patients' subjective evaluation with the use of SWN and DAI scales was compared with physicians' objective evaluation with the use of PANSS, CDS and CGI scales. RESULTS: The treatment with olanzapine caused significant improvement of schizophrenia positive, negative and affective symptoms. The use of the DAI questionnaire revealed also subjective improvement after olanzapine treatment. The decrease of schizophrenic symptoms correlated with the improvement of patients' subjective feeling of self-control, psychic functioning and somatic health. No serious adverse events were seen during the treatment. The severity of adverse events decreased during the olanzapine treatment. CONCLUSIONS: Olanzapine treatment of patients suffering from schizophrenia proved to be efficacious in both objective and subjective evaluation.

Adult↗